Investor Presentaiton

Response rate, % Immunology LPA₁ Sotyktu CD19 NEX T SLE Phase 2 data demonstrates compelling efficacy across domains Response rate, % Skin Domain: CLASI-501,2 Baseline CLASI activity score ≥ 10 with ≥ 50% decrease from baseline > Patient response treated with deucravacitinib in the PAISLEY Phase 2 study4 100 80 60 P<0.001 69.6 62.1 56.0 40 16.7 20 n = 24 n = 23 n = 25 0 n = 29 Week 48 Joint Domain: Joint Count-501,3 ≥ 6 active (tender + swollen) joints at baseline, with ≥ 50% decrease from baseline 100 80 68.3 40 20 642 56.5 60 52.3 45.3 Placebo 0 n = 64 n = 63 n = 65 n = 62 deucravacitinib 3 mg BID Week 48 deucravacitinib 6 mg BID deucravacitinib 12 mg QD Baseline Near complete resolution Day 1 Week 40 Day 1 Ill Bristol Myers Squibb™ 1. Morand E, et al. Arthritis & Rheumatology. 2023 Feb;75(2):242-252. 2. Multiplicity-adjusted secondary end point; A 52.9 (95% CI, 21.7-72.7), OR: 10.5 (95% CI, 2.5-43.0). 3. Exploratory non-multiplicity-controlled end point; 4. NCT03252587, Images used with investigator permission Not for Product Promotional Use 63 Week 20

View entire presentation